2022 DCP TRIAL Chlorthalidone compared with hydrochlorothiazide for the preven- tion of cardiovascular events in patients with hypertension: The Diuretic Comparison Project (DCP) Open-label, pragmatic, randomized controlled trial Objective: To compare the differences between hydrochlorothiazide (HCTZ) compared with chlorthalidone in improving cardiovascular outcomes among patients with hypertension 13523 patients Inclusion criteria: Patients >65 years on […]
Tag: hypertension
TIME Trial Summary: Morning vs. Evening dose of Antihypertensives
2022 TIME TRIAL Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK prospective, open-label, blinded-endpoint, randomized controlled trial IM Objective: To compare the major cardiovascular outcomes of evening dosing of antihypertensive medication versus morning dosing in patients with hypertension treated with their usual antihypertensive medications 21104 patients […]
SUPPORT Trial Summary: Olmesartan in CHF
2015 SUPPORT TRIAL M Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure (CHF) prospective, open-label, randomized controlled trial Objective: to examine whether an additive treatment with an ARB, olmesartan, reduces the mortality and morbidity of hypertensive patients with stable CHF 1147 Patients Inclusion criteria: Patients aged ≥20 & <80 […]
ALLHAT-LLT Trial Summary: Pravastatin in Moderate HLD
2002 ALLHAT-LLT Pravastatin vs Usual Care in Moderately Hypercholesterolemic, Hypertensive Patients Multicenter, randomized, nonblinded trial M Objective: To determine whether pravastatin compared with usual care reduces all-cause mortality in older, moderately hypercholes- terolemic, hypertensive participants with at least 1 additional CHD risk factor. Inclusion criteria: Ambulatory persons, aged 55 years or 10,355 older, with low-density […]
PADN-CFDA Trial Summary: PA Denervation for PAH
2022 PADN-CFDA TRIAL Pulmonary artery denervation for pulmonary arterial hypertension (PAH) multicenter, sham-controlled single-blind, randomized controlled trial Objective: To evaluate the treatment effects of pulmonary artery denervation (PADN) among patients with Group I PAH who were not on PAH-specific drugs 128 Patients Patients aged 18-70 years with WHO Group I PAH: mean pulmonary arterial pressure […]
ACCOMPLISH Trial: Benazepril + Amlodipine or HCTZ for Hypertension
2008 ACCOMPLISH TRIAL Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients Multi-centered, double-blind, randomized, controlled trial Objective: To evaluate the effect of amlodipine vs. hydrochlorothiazide in patients with hypertension and at high risk for cardiovascular disease. E 11,506 Inclusion criteria: Hypertension and high risk with age > 60 years old, systolic BP > […]
ACCORD BP Trial Summary: Intensive BP Control in Type 2 Diabetes
2010 ACCORD BP TRIAL Effects of intensive blood-pressure control in type 2 diabetes mellitus Multicenter, randomized, controlled, open-label trial Objective: In patients with T2DM at high risk for CV events, does intensive BP control (SBP <120 mmHg) reduce rates of nonfatal MI, nonfatal stroke, or CV mortality when compared to standard BP control (SBP <140 […]
INPRESS Trial Summary: Blood Pressure Management in Patients Undergoing Major Surgery
2017 INPRESS TRIAL Effect of individualized vs standard blood pressure management strategies on postoperative organ dysfunction among high-risk patients undergoing major surgery. Multicenter, randomized, parallel-group clinical trial Objective: To evaluate reduction in post-op organ dysfunction with Pan individualized BP management strategy as compared to standard practice in high-risk patients undergoing surgical procedures. 5 298 Inclusion […]
CHAP Trial Summary: Chronic Hypertension in Pregnancy
2022 CHAP TRIAL Treatment for Mild Chronic Hypertension during Pregnancy Open-label, multicenter, randomized trial Objective: To assess if treating mild chronic hypertension during pregnancy with a BP goal of <140/90 mmHg would lower incidence of adverse maternal and perinatal outcomes than a strategy of withholding treatment until the BP was 160/105 mm Hg or higher […]